Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06162572 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase 1 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Servier Bio-Innovation.
- Active
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT06162572 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by Servier Bio-Innovation. The registered enrollment target is 100 participants, below the 287-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT06162572, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by Servier Bio-Innovation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.
Conditions Studied
Interventions
- DRUG S095018
- DRUG S095024
- DRUG S095029
- DRUG S095018 Recommended Dose Expansion (RDE)
- DRUG S095024 RDE
Study Locations (20)
Other
- Instituto Médico Especializado Alexander Fleming - Buenos Aires
- Sanatorio Parque S.A. - Santa Fe
- Border Medical Oncology Research Unit - Albury
- Flinders Medical Centre - Bedford Park
- Sunshine Hospital - St Albans
- Latrobe Regional Health - Traralgon
- Ordensklinikum Linz Elisabethinen - Linz
- Universitatsklinikum St. Poelten - Sankt Pölten
- Medical University of Vienna - Akh - Vienna
- Jessa Ziekenhuis - Hasselt
- Uz Leuven Campus Gasthuisberg - Leuven
- Hospital de Amor - Barretos - Barretos
- Supera Oncologia - Chapecó
- CIONC - Curitiba
Ohio
- Gabrail Cancer Center - Canton
- Ohio State University Comprehensive Cancer Center - Columbus
California
- Loma Linda University - Loma Linda
Michigan
- Henry Ford Health - Detroit
Nevada
- Comprehensive Cancer Center of Nevada - Las Vegas
Virginia
- Virginia Cancer Specialists, P.C. - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06162572
The ClinicalTrials.gov registry entry for NCT06162572 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 287-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (65% lower). The listed sponsor is Servier Bio-Innovation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 5 interventions - of which S095018 is the first listed.
NCT06162572 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT06162572 about?
NCT06162572 is a clinical study titled "Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)". This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with...
What is the current status of trial NCT06162572?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-08-07. Estimated completion is 2027-07.
What conditions does trial NCT06162572 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT06162572?
The interventions under investigation include: S095018 (DRUG), S095024 (DRUG), S095029 (DRUG), S095018 Recommended Dose Expansion (RDE) (DRUG), S095024 RDE (DRUG).
Who is sponsoring clinical trial NCT06162572?
This trial is sponsored by Servier Bio-Innovation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06162572 being conducted?
This trial has 20 study locations across California, Michigan, Nevada, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.